%%USERNAME%%    %%ACCWORDS%% %%ONOFF%% |
 |
Gathered mainly from international media sources December 2020 - March 2021 |
For recent entries click "Invalid Item"  These are news/opinion items which caught my eye. Click on the link below: 31 Mar 2021 "Invalid Entry" 24 Mar 2021 "Invalid Entry" "Invalid Entry" 22 Mar 2021 "Invalid Entry" 21 Mar 2021 "Invalid Entry" "Invalid Entry" 19 Mar 2021 "Invalid Entry" "Invalid Entry" 17 Mar 2021 "Invalid Entry" "Invalid Entry" 26 Feb 2021 "Invalid Entry" 25 Feb 2021 "Invalid Entry" 24 Feb 2021 "Invalid Entry" 22 Feb 2021 "Invalid Entry" "Invalid Entry" "Invalid Entry" 21 Feb 2021 "Invalid Entry" "Invalid Entry" 19 Feb 2021 "Invalid Entry" "Invalid Entry" 18 Feb 2021 "Invalid Entry" 16 Feb 2021 "Invalid Entry" 15 Feb 2021 "Invalid Entry" 14 Feb 2021 "Invalid Entry" 9 Feb 2021 "Invalid Entry" 8 Feb 2021 "Invalid Entry" 4 Feb 2021 "Invalid Entry" 30 Jan 2021 "Invalid Entry" 29 Jan 2021 "Invalid Entry" 28 Jan 2021 "Invalid Entry" 27 Jan 2021 "Invalid Entry" 26 Jan 2021 "Invalid Entry" "Invalid Entry" "Invalid Entry" 24 Jan 2021 "Invalid Entry" 23 Jan 2021 "Invalid Entry" "Invalid Entry" 21 Jan 2021 "Invalid Entry" 20 Jan 2021 "Invalid Entry" "Invalid Entry" 19 Jan 2021 "Invalid Entry" "Invalid Entry" 18 Jan 2021 "Invalid Entry" 14 Jan 2021 "Invalid Entry" 12 Jan 2021 "Invalid Entry" 11 Jan 2021 "Invalid Entry" 10 Jan 2021 "Invalid Entry" 4 Jan 2021 "Invalid Entry" "Invalid Entry" "Invalid Entry" 2 Jan 2021 "Invalid Entry" 29 Dec 2020 "Invalid Entry" "Invalid Entry" 27 Dec 2020 "Invalid Entry" 24 Dec 2020 "Invalid Entry" 23 Dec 2020 "Invalid Entry" "Invalid Entry" 22 Dec 2020 "Invalid Entry" "Invalid Entry" "Invalid Entry" "Invalid Entry" 20 Dec 2020 "Invalid Entry" 19 Dec 2020 "Invalid Entry" 18 Dec 2020 "Invalid Entry" "Invalid Entry" "Invalid Entry" "Invalid Entry" "Invalid Entry" "Invalid Entry" "Invalid Entry" "Invalid Entry" "Invalid Entry" "Invalid Entry" "Invalid Entry" "Invalid Entry" 17 Dec 2020 "Invalid Entry" "Invalid Entry" 16 Dec 2020 "Invalid Entry" "Invalid Entry" 15/12/20 "Invalid Entry" 13 Dec 2020 "Invalid Entry" 12 Dec 2020 "Invalid Entry" "Invalid Entry" 11 Dec 2020 "Invalid Entry" "Invalid Entry" "Invalid Entry" "Invalid Entry" "Invalid Entry" "Invalid Entry" "Invalid Entry" "Invalid Entry" "Invalid Entry" For earlier entries drill down the list 10 Dec 2020 - Covid: Genes hold clues to why some people get severely ill 10 Dec 2020 - Referendum for the state of Texas to secede from the U.S. ? 10 Dec 2020 - Covid-19: More single day dead than in 9/11 terror attack or on D-Day landing 10 Dec 2020 - Covid-19: France moves to night-time curfew from 15 December 10 Dec 2020 - Elon Musk has launched the latest prototype of his Starship vehicle from Texas. 9 Dec 2020 - Covid-19 - $600 direct payment to most Americans? 9 Dec 2020 - Hunter Biden under federal investigation 9 Dec 2020 - Pfizer's COVID-19 vaccine data gets positive FDA review 9 Dec 2020 - Is BIG TECH censoring different ideas about COVID-19? 9 Dec 2020 - Clashes in Portland 9 Dec 2020 - UK is investigating two possible allergic reactions to Pfizer coronavirus shot 9 Dec 2020 - Open letter by the Prime Minister of Hungary to the European Union 9 Dec 2020 - VACCINE OPTIMISM AND PESSIMISM 9 Dec 2020 - UK EXIT FROM THE EU (Last supper?) 8 Dec 2020 - ROALD DAHL AND A WOKE APOLOGY |
| An Israeli-American pharmaceutical company is preparing to launch a Phase I clinical trial for what could become the world’s first oral COVID-19 vaccine. Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company based on technology developed by Hadassah-University Medical Center, announced over the weekend a joint venture with Premas Biotech to develop a novel oral vaccine. Together they formed the company Oravax Medical Inc. The vaccine is based on Oramed’s “POD” oral delivery technology and Premas’s vaccine technology. Oramed’s technology can be used to orally administer a number of protein-based therapies, which would otherwise be delivered by injection. Oramed is in the midst of a Phase III clinical trial through the US Food and Drug Administration of an oral insulin capsule for type I and type II diabetics. Premas has been working on developing a vaccine against the novel coronavirus since March. The companies connected earlier this year, according to Oramed CEO Nadav Kidron, and quickly realized that they could revolutionize the marketplace. “An oral COVID-19 vaccine would eliminate several barriers to rapid, wide-scale distribution, potentially enabling people to take the vaccine themselves at home,” Kidron said. “While ease of administration is critical today to accelerate inoculation rates, an oral vaccine could become even more valuable in the case that a COVID-19 vaccine may be recommended annually like the standard flu shot.” The company completed a pilot animal study and found that the vaccine promoted the development of Immunoglobulin G (IgG) antibodies and Immunoglobulin A (IgA). IgA is necessary for longer-term immunity. The new Oravax vaccine candidate targets three structural proteins of the novel coronavirus, Kidron explained, as opposed to the single spike protein targeted via the Moderna and Pfizer vaccines. As such, “this vaccine should be much more resistant to COVID-19 variants,” Kidron claimed. In addition, it is a yeast-based vaccine, making the time and cost of production much cheaper than its already-approved competitors. The advantages of an oral vaccine go beyond safety and efficacy, Kidron continued. He said that oral medications tend to have fewer side effects; around 10% of people who are inoculated by Pfizer or Moderna report having some adverse effects. In addition, the vaccine can be shipped at refrigerator temperatures and even stored at room temperature, “making it logistically easier to get it anywhere around the world,” Kidron said. Finally, an oral vaccine would not require professional administration. Oravax anticipates commencing a clinical study during the second quarter of 2021. Kidron said that it is applying for trials in multiple countries, including the United States, Israel, Europe and Mexico. It hopes to also target Africa, where such an oral vaccine could prove essential. Kidron said he expects Phase I human trial data to be available within three months. In February 2020, shortly after the start of the COVID-19 pandemic, another Israeli team began development on what they hoped would be an oral coronavirus vaccine. Scientists from the Galilee Research Institute’s biotechnology group who had been developing a vaccine against avian coronavirus, which had been proven effective in preclinical trials and they believed would translate to a human vaccine, said that they were primed to develop their vaccine within a few short months. |
| Eastern Vaccine Reports coming out of Hungary suggest many doctors are refusing to administer Covid vaccines imported from Russia and China. |
View Portfolio
Visit Notebook
Send Gift Points
Awards
Badges
Send Email
Community Newsfeed
General Discussion
Sponsored Items
Book of Trinkets
Static Items
Books
Groups
Interactive Stories
Audio
Campfire Creatives
Community Notes
Crossword Puzzles
Documents
Folders
Images
In & Outs
Madlibs
Photo Albums
Polls
Product Reviews
Quizzes
Survey Forms
Web Pages
Word Searches
